Home
Bipolar Disorder Cause Resources
Top Links
Bipolar Syndrome Links
Terms of Service
Privacy Policy
Sitemap

Navigation

Bipolar medication websites
Bipolar disorder therapy
Treatments for symptoms
Bipolar type two
Names of bipolar medications
Types of bipolar
Bipolar
Bipolar screening test
Bipolar disorder
Bipolar type 2
Tests for bipolar disorder
Medicines for bipolar disorder
Bipolar disorder definition
Medication for bipolar patients
Bipolar symptoms in children

Books


The Sedona Method Self Improvement Course
Bipolar Symptoms News

New Book Helps Those with Bipolar Disorder Manage Diets - and Lives

(PRWEB) August 5, 2009 -- Author http://www.bipolar-lives.com/ [Sarah Freeman] has overcome many challenges when it comes to dealing with her bipolar disorder. Now, she hopes to share some of the...

Read more...


Bipolar Advantage Announces New Program 'Providing Solutions to the Bipolar Economy'

Read more...


New Scholarship for Leaders of Bipolar Lives

Tallahassee, Florida (PRWEB) July 6, 2008 -- What do you do when you want to let the bipolar community know about scholarships for people with bipolar disorder, but soon discover that support for...

Read more...


2007 Bipolar Disorder Awareness Campaign Emphasizes Importance of Accurate Diagnosis, Treatment and Recovery

Washington, DC (PRWEB) October 11, 2007 -- The http://www.nami.org [National Alliance on Mental Illness __title__ National Alliance on Mental Illness](NAMI) today launched its fifth annual...

Read more...


MSD Receives European Approval Of Its Atypical Antipsychotic Medication SYCREST(R) For The Treatment Of Manic Episodes ...

MSD (MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A). announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations ...

Read more...